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Abstract
New antifungal drugs are urgently needed due to the currently limited selection, the emergence of drug resistance, and the
toxicity of several commonly used drugs. To identify drug leads, we screened small molecules using a Saccharomyces
cerevisiae reporter bioassay in which S. cerevisiae heterologously expresses Hik1, a group III hybrid histidine kinase (HHK)
from Magnaporthe grisea. Group III HHKs are integral in fungal cell physiology, and highly conserved throughout this
kingdom; they are absent in mammals, making them an attractive drug target. Our screen identified compounds 13 and 33,
which showed robust activity against numerous fungal genera including Candida spp., Cryptococcus spp. and molds such as
Aspergillus fumigatus and Rhizopus oryzae. Drug-resistant Candida albicans from patients were also highly susceptible to
compounds 13 and 33. While the compounds do not act directly on HHKs, microarray analysis showed that compound 13
induced transcripts associated with oxidative stress, and compound 33, transcripts linked with heavy metal stress. Both
compounds were highly active against C. albicans biofilm, in vitro and in vivo, and exerted synergy with fluconazole, which
was inactive alone. Thus, we identified potent, broad-spectrum antifungal drug leads from a small molecule screen using a
high-throughput, S. cerevisiae reporter bioassay.
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Introduction
Over the past twenty years, the incidence of fungal infections
has risen sharply as advances in medicine have increased the
number of immunocompromised patients [1]. Unfortunately, the
antifungal drug armamentarium has not kept pace. Current
antifungal therapeutics are plagued with problems including
limited spectrum of activity, the emergence of resistant strains,
and patient toxicity [2]. New drugs are required to meet the
growing need for antifungal therapy.
The identification of novel antifungals is hindered by the
limited number of drug targets that are unique to fungi due to the
close evolutionary relationship between fungi and mammals.
Hybrid histidine kinases (HHKs) are an appealing antifungal
drug target due to their central role in fungal physiology,
conservation throughout the fungal kingdom, and absence in
mammals. HHKs regulate two-component signaling pathways
in response to a variety of environmental stimuli, including
osmotic, nitrosative, and oxidative and stress in bacteria and
fungi [3].
Two-component signal transduction cascades contain a sensor
kinase and a response regulator. The sensor kinase regulates the
pathway via phosphotransfer, where the kinase autophosphor-
ylates a histidine residue and then transfers the phosphate to an
aspartate on the response regulator. A hybrid histidine kinase
contains both a kinase and a response regulator domain. Analysis
of several fungal genomes has revealed 11 distinct HHK groups
based on phylogenetic analysis of protein sequence [4]. Among
these groups, the group III HHKs are the most attractive drug
target due to their diverse regulon, which includes pleotropic
phenotypes such as morphogenesis, virulence factor expression,
and cell wall biogenesis. Group III HHKs contribute to virulence
in the two most common systemic human fungal pathogens,
Aspergillus fumigatus [5] and Candida albicans [6], and they regulate
the phase transition, sporulation, and virulence factor expression
in the dimorphic fungal pathogens Blastomyces dermatitidis and
Histoplasma capsulatum [3,7].
Group III HHKs in C. albicans, A. fumigatus, and Magnaporthe
grisea are a target of the agricultural antifungal compound
fludioxonil. Deletion of the group III HHK in these fungi renders
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expression of the group III HHK, Hik1, from M. grisea in S.
cerevisiae confers sensitivity to fludioxonil, although the S. cerevsiaie is
naturally resistant to the compound because it lacks an endoge-
nous group III HHK [11]. Therefore, fludioxonil kills fungi in a
group III HHK-dependent manner whether the encoding gene is
expressed endogenously and heterologously.
We sought to exploit the fact that HHKs render fungi
exquisitely sensitive to drugs that target this signaling pathway to
identify candidate compounds with broad and potent antifungal
activity. We harnessed a Hik1-expressing strain of S. cerevisiae as a
cell-based reporter to develop a high throughput screen for
compounds with group III HHK-dependent activity. After
screening compound libraries, we identified two novel compounds
that exerted significant activity across multiple genera of human
fungal pathogens, including mold, yeast, and drug-resistant patient
isolates. Analysis revealed that these compounds do not act directly
on HHKs. However, microarray analysis provided insight into
their modes of action and these compounds exhibit promising
features as strong leads for drug development including robust,
fungicidal activity against in vitro and in vivo C. albicans biofilm and
synergy with fluconazole.
Materials and Methods
Fungal strains and growth conditions
The fungal strains used in this study were mostly human patient
isolates and are listed in Table S1. In addition to C. albicans and A.
fumigatus, they included non-albicans Candida spp., Cryptococcus spp.,
Rhizopus oryzae and Fusarium solani.T h eSaccharomyces cerevisiae reporter
strain heterologously expresses Hik1, a group III HHK from
Magnaporthe grisea, under the regulation of the galactose promoter,
gal1, and was generously provided by Takayuki Motoyama from
RIKEN (Wako, Japan). S. cerevisiae was incubated at 30uC. Complete
medium was yeast peptone dextrose (YPD), and the minimal
mediumwasyeastsyntheticcomplete (SC)[12].Candida spp.cultures
were maintained on YPD at 30uC. Cryptococcus spp., Aspergillus spp.,
R. oryzae,a n dF. solani were grown on YPD at 37uC.
High-throughput screen for small molecules
The small molecule screen was performed in three stages
(Figure 1). In the primary screen, the S. cerevisiae strain expressing
Hik1 underthecontrolofa galactose-induciblepromoterwas seeded
at 0.1 OD600 nm in 96-well plates containing SC media that lacked
uracil and contained galactose. Small molecules (Maybridge
Chemical Company; NIH Clinical Collection; Prestwick Chemical)
were screened at a concentration of 10 mM. Wells containing media
and fludioxonil (Sigma) served as negative and positive controls,
respectively. The plate was incubated at 30uC overnight and growth
was quantified by measuring OD600 nm with a plate reader.
Compounds that caused a growth reduction .50%, relative to
medium control were subjected to a second screen.
In the secondary screen to determine if the growth inhibition
was Hik1-dependent, compounds were re-tested against the
parental and Hik1-expressing Saccharomyces strains. The Hik1-
expressing strain was grown under the same conditions as above,
while the parental strain was grown in SC plus uracil with glucose.
Small molecules that reduced the growth of the Hik1-expresing
strain by .50%, and the parental wild-type strain by ,10% were
considered hits.
Antifungal disk diffusion assay
0.5% top agar was seeded at 1.5610
4 yeast/ml from an
overnight culture of C. albicans grown in YPD medium. 600 mlo f
top agar C. albicans suspension was added to each well of a 6-well
plate containing 5 ml of YPD solid media. After the top agar
solidified, sterile 6-mm paper discs (Fisher) containing 10 mgo f
small molecule were placed in each well. The compounds were
stable and kept as a powder until they were compounded for
testing in assays. A DMSO (Sigma) containing disc was added to
each plate as a negative control. The plates were incubated at
37uC for 24 hrs, and activity was assessed based on the size of the
zone of inhibition. Disk diffusions with A. fumigatus were performed
following the same protocol, with the only difference being that the
top agar was seeded with 1610
6 conidia/ml.
Measurement of drug minimal inhibitory concentration
(MIC) against fungi
The MIC of compounds against Candida spp. and Cryptococcus
spp. was determined following CLSI protocol M27-A3. Briefly,
overnight liquid cultures of Candida spp. or Cryptococcus spp. grown
in YPD were enumerated using a hemocytometer, suspended in
RPMI (Sigma) buffered with MOPS (Sigma) to pH 7.0 (RPMI/
MOPS) to a density of 3610
3 per ml, and 100 ml of yeast was
added to 96-well plates containing media and drug titrations in
triplicate. The plates were incubated overnight at 37uC and the
MIC was defined as the lowest concentration that prevented
visible growth. The reported MICs are representative of at least
two independent experiments. The MIC of compounds against A.
fumigatus, R. oryzae, and F. solani was determined following CLSI
protocol M38-A2, which is identical to M27-A3 protocol except
that the seeding inoculum was at 2610
4 spores/ml. The
commercial antifungal drugs fluconazole, voriconazole, and
amphotericin B were purchased from the pharmacy of the
University of Wisconsin Hospital and Clinics, Madison, WI.
The fungicidal or fungistatic activity of each compound against
the isolates was determined as follows: A 100 ml aliquot was
removed from the well representing the MIC of the compound,
and spread onto a YPD plate. Wells containing isolates exposed to
media alone or DMSO were plated as controls. The plates were
incubated at 37uC for 48 hours, and compounds that prevented
visible growth were considered fungicidal.
RNA isolation from C. albicans after compound 13 or 33
exposure
A time course of C. albicans exposure to compounds was
performed as follows. Briefly, an overnight culture of C. albicans
grown in YPD at 37uC was diluted to 0.1 OD600 and grown at
37uC to exponential phase (0.4–0.5 OD600). After the incubation
period, compounds were added at concentrations that caused a
50% reduction in CFU after a 3.5-hour incubation compared to
DMSO (0.75 mg/ml for compound 13 and 3 mg/ml for compound
33). Samples were collected at 0, 20, 40 and 60 minutes. The cells
were pelleted, supernatant was removed, and the cell pellet was
flash frozen with liquid nitrogen. Samples were stored at 280uC
until processed for RNA isolation.
RNA was extracted following the yeast RNA extraction
protocol from the RNeasy Mini/Maxi Handbook (Qiagen). After
RNA isolation, the sample was applied to a RNeasy Maxi Spin
column and DNase (Ambion) treated according to the kit protocol.
The RNA quality and integrity was verified with an Agilent 2100
Bioanalyzer (Agilent Technologies).
Microarray analysis
cDNA labeling and microarray hybridizations were performed
as described [13]. Briefly, dye-swapped duplicate hybridizations
were performed on biological replicates for each time point (t=0,
Antifungal Drug Discovery
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Briefly, 20 mg of total RNA was reverse transcribed using 9 ng of
oligo(dT)21 in the presence of Cy3 or Cy5-dCTP (Invitrogen) and
400 U of Superscript III reverse transcriptase (Invitrogen). After
cDNA synthesis, template RNA was degraded by adding 2.5 units
RNase H (Promega) and 1 mg RNase A (Pharmacia) followed by
incubation for 15 min at 37uC. The labeled cDNAs were purified
with QIAquick PCR Purification Kit (Qiagen). Prior to hybrid-
ization Cy3/Cy5-labeled cDNA was quantified using a NanoDrop
ND-1000 UV-VIS spectrophotometer (NanoDrop) to confirm dye
incorporation. The labelled cDNA was hybridized to microarrays
spotted with 6037 70mer oligonucleotide probes (GEO Platform
GSE25822). Fluorescence intensity data was analyzed in Gene-
spring Gx version 7.3 (Agilent Technologies) and MultiExperi-
ment Viewer 4.7 (http://www.tm4.org/mev/). To account for
changes in transcriptional profiles that occurred between t=0 and
t=60, the drug-treated fluorescence ratios for each gene at t=20,
40 and 60 min were divided by their ratios at t=0. Data was
reduced by selecting 1180 genes with a 2-fold change in transcript
abundance under at least two conditions and visualized by
hierarchical clustering.
Gene set enrightment analysis (GSEA) [14] was performed on
the t=20 min data using the GSEA Preranked tool and the
weighted enrichment statistics on 6387 gene sets each containing
5–500 genes. Statistical significance was estimated from 1000
permutations. Enrichment maps were constructed with Cytoscape
2.8 [15] and the Enrichment Map 1.1 plug-in using the default
settings.
Heavy Metal Stress
Flasks containing YPD were seeded with 1500 yeast/mL from a
6-hr culture of C. albicans grown at 30uC shaking at 250 rpm.
Figure 1. Hik1 Saccharomyces bioassay small molecule screen schematic. The small molecule screen was performed in three steps. (I) The
Hik1-expressing Saccharomyces strain was seeded into 96-well plates containing 10 mM of small molecules. Media and fludioxonil containing wells
served as negative and positive controls respectively. Hit compounds were defined as molecules that inhibited growth by at least 50% after overnight
incubation at 30uC (black circle). (II) Hit compounds were assayed against parental and Hik1-expressing Saccharomyces to identify only molecules
with Hik1-dependent activity. Compounds that inhibited the growth of both strains were discarded (black crosses). Molecules that inhibited Hik1-
Saccharomyces growth by at least 50%, but did not hinder growth of the parental strain by more than 10% were considered hits (black circle). (III)
Activity against the fungal pathogens C. albicans and A. fumigatus was assessed by disc diffusion. Top agar was seeded with yeast or spores,
compound containing discs were then placed on the solidified agar, and the plates were incubated overnight at 37uC. Compounds that generated
zones of inhibition (white circle) against both organisms were subjected to further analysis.
doi:10.1371/journal.pone.0036021.g001
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two-fold dilutions. After overnight incubation shaking at 30uC, 96-
well round bottom plates were seeded with 50 mlo fC do r
medium-exposed yeast at 1500 yeast/mL. Each pretreatment
group was exposed to 50 ml YPD containing compound 33 (0.125–
0.500 mg/ml), solvent control, or medium alone in triplicate. After
incubation at 30uC overnight, growth was assessed using the XTT
assay and growth reduction was determined relative to medium
control.
Hemolytic assay of compound toxicity
Compound hemolytic activity was assessed as described [16].
Briefly, freshly obtained human red blood cells (RBC) were
washed three times with PBS and centrifuged at 2500 rpm for five
minutes. A suspension of 1% RBC in PBS was added to 96-well
plate containing two-fold dilutions of drugs ranging from 300–
0.3 mg/ml in triplicate. PBS and 1% Triton X-100 (Sigma) served
as negative and positive controls. After a 1-hour incubation at
37uC, the plate was centrifuged at 1500 rpm for five minutes and
50 ml of supernatant was transferred to a fresh 96-well plate.
Hemoglobin release was quantified by measuring OD405 nm and
values of the compound-only control plate were subtracted to
remove any drug absorbance. The OD of cells exposed to 1%
Triton X-100 represented 100% lysis; the OD of cells incubated in
PBS represented O%.
C. albicans in vitro biofilm assay
C. albicans biofilm sensitivity to drug was assessed using an in vitro
assay as described [17]. Briefly, RPMI (Sigma), buffered to pH 7.0
with MOPS (Sigma), was seeded with 1610
6 yeast/ml from an
overnight C. albicans (SC5314) grown in YPD at 30uC. The interior
wells of flat-bottom 96-well plates were seeded with 100 ml of the
yeast suspension. The exterior wells were filled with 200 ml PBS.
The plate was wrapped in parafilm and foil and incubated at 37uC
for 6 hours. The plate was gently washed twice with PBS. One
column of wells was filled with media to serve as a growth control.
The remaining columns were seeded in triplicate with compound,
fluconazole, or amphotericin B in two-fold dilutions ranging from
0.1–25 mg/ml. After overnight incubation at 37uC, plates were
gently washed twice with PBS. The tetrazolium dye, XTT (sodium
2,3,-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)-car-
bonyl]-2H-tetrazolium inner salt) (Sigma) was used to assay the
viability of cells [18]. Growth reduction was determined relative to
the medium control based on OD490 nm.
The in vitro biofilm assay was also used to measure compound
synergy with fluconazole as described [19]. After incubation to
allow biofilm formation, compound 13 or 33 (0.4–25 mg/ml) and
fluconazole (62.5–1000 mg/ml) were added to wells alone and in
combination to 96-well plate. The XTT assay was used to
determine growth reduction of drug-treated wells relative to
media-treated wells. Synergy was quantified using the fractional
inhibition concentration (FIC) that resulted in 25% growth
reduction. FIC was calculated using the formula: [(EC25 of drug
A in combination/EC25 drug A alone)+(EC25 of drug B in
combination/EC25 of drug B alone)]. Values #0.5 indicate
synergy.
In vivo rat denture model of a C. albicans biofilm
The in vivo efficacy of compounds was assayed using a C. albicans
biofilm denture model as described [20]. Briefly, specific-
pathogen-free male Sprague-Dawley rats (Harlan Laboratories)
were anesthetized and immunosuppressed with a single dose of
cortisone (200 mg/kg subcutaneously) one day prior to infection.
Dentures were then placed in the animals [20]. After the denture
material had solidified, the dentures were inoculated with 100 ml
of a 1610
8 cells/ml C. albicans solution. C. albicans biofilms were
topically treated with compounds 13 (20 mg/ml), 33 (40 mg/ml), or
saline control once per day. After 48 hours of treatment, the
animals were sacrificed and the devices were removed. The
dentures were placed in 2 ml 0.15 M NaCl, sonicated for ten
minutes and vortexed. The viable burden of C. albicans was
quantified by measuring colony-forming units (CFU) on agar at
30uC. Serial dilutions (1:10) were plated on Sabouraud dextrose
agar (Sigma) containing 2.5 mg/ml chloramphenicol and incubat-
ed at 30uC.
Statistical analysis
The effect of pretreatment with heavy metal on the sensitivity of
C. albicans to compound 33 was analyzed by two-way ANOVA.
The burden of C. albicans in rat denture biofilm and the results of
C. albicans biofilm sensitivity to compounds were assessed via an
unpaired t-test. All statistical evaluations were performed using
Graphpad Prism software (Version 5.0d for Mac OS X). P values
of ,0.05 were considered significant.
Ethics Statement
The University of Wisconsin Animal Care and Use Committee
approved all work with animals in this study. The Institutional
Review Board approved collection of peripheral blood from
volunteer donors who provided appropriate written consent.
Results
Identification of compounds 13 and 33 using a Hik-1
reporter bioassay
We performed a high-throughput, target-based screen to
identify compounds that act in an HHK-dependent manner
against the Hik1-expressing Saccharomyces reporter strain (Figure 1).
In the primary screen, 19,762 small molecules and the positive
control fludioxonil were assayed for activity against the reporter
strain. Fludioxonil and 314 (1.6%) of the small molecules inhibited
S. cerevisiae growth by more than 50% (Table 1). In the secondary
screen to assess whether the small molecules acted in a Hik1-
dependent manner, 57 of the small molecules inhibited the growth
of the reporter strain by more than 50%, and the parental S.
cerevisiae strain by less than 10% (Table 1). Thus, 57 compounds
were carried forward as candidates for further testing against
pathogenic fungi, using disk diffusion assays.
Robust activity against C. albicans and A. fumigatus is a high
priority for antifungal drug leads, since these are the two most
prevalent and medically significant, systemic fungal pathogens.
Disk diffusion experiments revealed that 15 of the small molecules
generated visible zones of inhibition against both fungi (Table 1).
Of these 15 candidates, compounds 13 and 33 produced the
Table 1. Hik1 Saccharomyces cerevisiae small molecule screen
results.
Screen # Compounds tested # Hits
Primary Screen 19,762
{ 314
Secondary Screen 314 57
Disk Diffusion Screen 40 15
{18,432 compounds from Maybridge HitFinder Collection; 1,150 compounds
from NIH Clinical Collection; 880 compounds from Prestwick Chemical Library.
doi:10.1371/journal.pone.0036021.t001
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they became the focus of our further studies. Compounds 13 and
33 are heterocyclic compounds containing nitro group(s), which is
a structure similar to the commercial antimicrobial nitrofurantoin
(Figure 2).
Compounds 13 and 33 show potent, broad-spectrum
antifungal activity
Because agar disk diffusion assays are only qualitative measures
of activity, we performed quantitative assays. Using broth
microdilution assays, compounds 13 and 33 were highly active
against fungal pathogens spanning multiple genera, including
pathogenic molds (Table 2). The MICs of compounds 13 and 33
against a collection of 20 isolates of A. fumigatus were 0.39 mg/ml
and 0.39–0.78 mg/ml, respectively, which was in the range of
those measured for voriconazole (0.20–1.56) and amphotericin B
(0.20–1.56) (Table 2). Compound 33 yielded an MIC of 0.39 mg/
ml against Fusarium solani, which was similar in potency to the
activity measured for amphotericin B (Table 2). Rhizopus oryzae
isolates were highly sensitive to compound 13 (MIC 0.2-0–
0.39 mg/ml) and 33 (MIC 0.78–1.56 mg/ml), and also to
amphotericin B (MIC 0.20 mg/ml) (Table 2).
Compounds 13 and 33 were also highly active against
pathogenic yeast, showing similar potency to the conventional
antifungals. We tested several pathogenic species of Candida. C.
albicans exhibited respective MICs of 0.25–0.50, 0.25–0.50, 0.50–
0.78, and 0.13–0.25 mg/ml for compounds 13 and 33, fluconazole,
and amphotericin B (Table 2). In contrast to C. albicans, Candida
glabrata showed high MIC values to compound 33, fluconazole,
and amphotericin B (MIC of 3.12–6.24, 3.13–.25, and 0.78 mg/
ml). However, all strains of C. glabrata were sensitive to compound
13 (MIC,0.25 mg/ml) (Table 2). The activity of compounds 13
and 33 against C. lusitaniae was similar to that of fluconazole, but
less than that for amphotericin B, with MICs of 1.56–3.12, 1.56–
3.12, 3.12–6.24, and ,20 mg/ml respectively (Table 2).
Compounds 13 and 33 also had potent activity against
Cryptococcus species. Cryptococcus neoformans was more susceptible to
compounds 13 and 33 than to fluconazole, showing MICs of 0.25,
0.13, and 2 mg/ml respectively (Table 2). Although both isolates of
C. gattii were resistant to fluconazole (MIC.25 mg/ml), com-
pounds 13 and 33 showed significant activity that was comparable
to amphotericin B with respective MICs of 0.39–0.78, 0.78, and
0.78 mg/ml (Table 2).
Compounds 13 and 33 were tested to determine if their activity
was fungistatic or fungicidal. Both compounds exerted fungicidal
activity against all of the fungal genera tested above, in the same
concentration range as observed for growth inhibition.
Compounds 13 and 33 show potent activity against
fluconazole-resistant strains of C. albicans
The emergence of C. albicans strains that are resistant to the
frontline drug fluconazole is a significant therapeutic problem
[21]. Fluconazole-resistant C. albicans isolates (MIC.25 mg/ml)
were highly sensitive to compounds 13 and 33, showing MIC
values of 0.25–0.50 mg/ml, which was similar to the values for
other C. albicans isolates (Table 2). Moreover, C. krusei, which is
naturally resistant to fluconazole (MIC values.25 mg/ml), was as
sensitive to compound 33 as amphotericin B, yielding MIC values
of 0.78–1.56 mg/ml and 1.56 mg/ml respectively (Table 2).
Direct activity of compounds 13 and 33 against HHKs in
pathogenic fungi
Deletion of group III HHK renders numerous fungi resistant to
fludioxonil [22–25]. To see if the activity of compounds 13 and 33
required HHKs in pathogenic fungi, we assessed the sensitivity of
A. nidulans wild type and group III HHK (NikA) knockout strains
to compounds 13 and 33 and fludioxonil (Table 3). Deletion of
NikA engendered resistance to fludioxonil. Wild type A. nidulans
had an MIC of 0.63 mg/ml and the DNikA strain, an
MIC.25 mg/ml (Table 3). In contrast, deletion of NikA had no
effect on the sensitivity of A. nidulans to compounds 13 or 33. Wild
type and DNikA strains had MICs of 3.13 mg/ml for both
compounds (Table 3). The thirteen other hits from the small
molecule screen also lacked group III HHK-dependent activity in
A. nidulans (data not shown).
Microarray analysis of C. albicans to discern compound
modes of action
We sought further insight into the mode of action of our
compounds since they exhibited such potent and broad-spectrum
activity against fungi. Transcripts of C. albicans were analyzed over
the course of compound exposure for 60 minutes (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?token=bvmtzccmsecqgbi&acc
=GSE35105). By 40 minutes of exposure, 285 transcripts were
upregulated and 362 transcripts were downregulated .2-fold in
response to compound 13. The respectivenumbers for compound 33
were 364 transcripts upregulated and 476 transcripts down-regulated
.2-fold (see File S1). Although some of the transcripts appeared
similarly modulated following the addition of either compound
(Figure S1), we did not observe a significant correlation between
genes that were upregulated with both compounds. In contrast, the
downregulated genes were mostly associated with GO terms such as
Transport, Carbohydrate and Lipid Metabolic Processes, Response
to Stress and Response to Drug. Comparison of the transcript
profileswithotherprofilesand annotationsbyGeneSetEnrichment
Figure 2. Small molecule structures. The chemical names of
compounds 13 and 33 are 2-nitro-5-(4-nitroStyryl)furan (MW=260.20)
and 2-(methylthio)-5-[(5-nitro-1,3-thiazol-2-yl)thio]-1,3,4-thiadiazole
(MW=292.39) respectively.
doi:10.1371/journal.pone.0036021.g002
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13 significantly up-regulated 48/127 transcripts associated with
oxidative stress [26] (Figure 3A) (Table S2) (File S2). Other gene sets
enriched among those upregulated by compound 13 were involved
in oxygen and reactive oxygen metabolic processing, antioxidant
activity, and oxidative stress (data not shown).
Exposure to compound 33 also lead to a unique signature of gene
expression. Sixty of the 107 genes associated with the heavy metal
stress response gene cluster [26] were upregulated upon incubation
with compound 33 (Figure 3B) (Table S3). The known heavy metal
stress-induced genes Cpr6, Sba1, and Sis1 were upregulated 6.65,
5.84, and 4.74 fold, respectively [26,27]. Therefore, oxidative
damage appears to be involved in the mode of action of compound
13, while compound 33 induces heavy metal stress.
Fungi deficient in DNA damage repair have increased
sensitivity to compound 13
Oxidative stress commonly results in DNA damage [28]. To
determine if DNA damage is involved in the action of compound
13 or 33, we assessed their activity against DNA repair-deficient
strains of C. albicans and A. nidulans (Table 4). The DNA repair-
deficient C. albicans were much more sensitive than the parental
strain to compound 13, with MICs of 0.08 mg/ml and 0.63 mg/ml
respectively (Table 4). The inability to repair DNA damage also
increased the sensitivity of A. nidulans to compound 13. The
mutant strain had an MIC of 0.16 mg/ml compared to an MIC of
0.63 mg/ml for the wild type. The inability to repair DNA damage
did not affect the sensitivity of either fungus to compound 33, with
all strains showing an MIC of 1.25 mg/ml (Table 4). Nor did DNA
repair-deficient fungi exhibit altered sensitivity to amphotericin B
(Table 4). These findings are compatible with a mode of action
mediated by compound 13 (but not 33) that involves oxidative
stress.
Pre-exposure to heavy metal enhances sensitivity to
compound 33. We hypothesized that pre-exposure to heavy
metal would alter the sensitivity of C. albicans to compound 33. Pre-
exposure of C. albicans to osmotic stress has been shown to alter its
resistance to subsequent exposure to the osmotic stress-inducing
peptide histatin 5 [29]. We found that pre-exposing C. albicans to a
heavy metal stress increased its sensitivity to compound 33
(Figure 4). Pre-exposure of C. albicans to cadmium in sub-lethal
amounts significantly enhanced sensitivity of C. albicans to
compound 33 in a concentration-dependent manner. Heavy
metal stress therefore may contribute to the mechanism of action
of compound 33.
Compound toxicity
Induction of DNA damage or oxidative stress might suggest
possible compound toxicity. We performed a standard assay of cell
membrane fragility assay to explore the toxicity of compounds 13
and 33 (Figure 5). Amphotericin B, a commonly used antifungal
drug known to damage cell membranes, lysed RBCs at drug
concentrations as low as 20 mg/ml, whereas compounds 13 and 33
failed to lyse these cells even at concentrations of 300 mg/ml,
which is well in excess of their MICs against fungi (Figure 5).
Activity of compounds 13 and 33 against drug-resistant
C. albicans biofilm
C. albicans forms biofilms on implanted medical devices. These
biofilms are resistant to the front-line drug fluconazole and
represent life-threatening bloodstream infections [30]. We assayed
activity of compounds 13 and 33 against C. albicans biofilm using
an in vitro assay (Figure 6A). Compounds 13 and 33 were more
active than fluconazole against C.albicans biofilms. Both com-
pounds reduced biofilm growth .50% at concentrations as low as
12.5 mg/ml, whereas fluconazole failed to inhibit C. albicans growth
by .30% even at elevated drug concentrations of 1000 mg/ml.
Table 2. Spectrum of activity of compounds 13 and 33 against pathogenic fungi.*
Organism 13 33 Fluconazole Voriconazole Amphotericin B
Candida albicans wild type (4) 0.25–0.50 0.25–0.50 0.50–0.78 NT
+ 0.13–0.25
Candida albicans drug-
resistant (3)
0.25–0.50 0.25–0.50 .25 NT 0.13–0.25
Candida glabrata (5) ,0.20 3.12–6.24 3.13–.25 NT 0.78
Candida krusei (3) 6.24–12.5 0.78–1.56 .25 NT 1.56
Candida lusitaniae (3) 1.56–3.12 1.56–3.12 3.12–6.24 NT ,0.20
Cryptococcus neoformans
var. grubii (1)
0.25 0.13 2 NT 0.06
Cryptococcus gattii (2) 0.39–0.78 0.78 .25 NT 0.78
Aspergillus fumigatus (20) 0.39 0.39–0.78 NT 0.20–1.56 0.20–1.56
Fusarium solani (1) 6.25 0.39 NT NT 0.39
Rhizopus oryzae (2) 0.20–0.39 0.78–1.56 NT NT 0.20
*Broth microdilution quantification of compound MIC (mg/ml) against yeast and filamentous fungal pathogens. The number of fungal strain isolates tested is in
parentheses. The values are representative of at least two independent experiments.
+NT=not tested.
doi:10.1371/journal.pone.0036021.t002
Table 3. Compounds 13 and 33 are not Group III HHK-
dependent in Aspergillus nidulans*.
Strain Compound 13 Compound 33 Fludioxonil
Wild Type 3.13 3.13 0.63
DNikA 3.13 3.13 .25
*Broth microdilution quantification of compound MIC (mg/ml) against parental
and DNikA strains of A. nidulans. The values are representative of three
independent experiments.
doi:10.1371/journal.pone.0036021.t003
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against C. albicans biofilms.
Compounds 13 and 33 exert synergy with fluconazole
against C. albicans biofilm
In view of the clinical utility of fluconazole, we explored
whether compounds 13 or 33 might act synergistically with
fluconazole against C. albicans biofilms. In vitro C. albicans biofilm
indeed was hypersensitive to a combination of 13 or 33 with
fluconazole (Figure 6B). The FIC indices of compounds 13 or 33
with fluconazole were 0.26 and 0.32, respectively, which indicate a
significant synergistic interaction of both compounds with
fluconazole (Table 5).
Compounds 13 and 33 are active in vivo against C.
albicans biofilm
In view of the significant activity of the compounds against C.
albicans biofilm in vitro, we evaluated their activity in vivo against C.
albicans biofilm. In initial studies, we ascertained that both
compounds exhibited significant protein binding (data not shown),
making serum levels negligible following systemic administration,
and treatment of systemic infection inconsistent. For this reason, to
minimize the confounding effects of protein binding, we studied
the activity of compounds 13 and 33 following topical application
in a rat denture model of C. albicans biofilm infection (Figure 7).
Compounds 13 and 33 each reduced the fungal burden of
dentures by more than one order of magnitude, when compared to
animals that received control treatment.
Figure 3. Microarray analysis of C. albicans exposed to
compounds 13 and 33. Changes in transcript expression of oxidative
(A) and heavy metal (B) stress response gene clusters during a time
course of C. albicans exposed to compounds 13 or 33. The fluorescence
intensity (i.e. transcript abundance) relative to the given transcript value
at time 0 is shown for C. albicans exposed to compound for 20, 40 and
60 minutes.
doi:10.1371/journal.pone.0036021.g003
Table 4. DNA repair-deficient fungi have an increased
sensitivity to compound 13 but not 33.*
Strain Compound 13 Compound 33 Amphotericin B
C. albicans wild type 0.63 1.25 0.63
DRad2 0.08 1.25 0.63
DRad10 0.08 1.25 0.63
A. nidulans wild type 0.63 1.25 20
DuvsJ1 0.16 1.25 .20
*The MIC (mg/ml) of compounds 13 and 33 and amphotericin B against C.
albicans and A nidulans strains was determined using the assay. These data are
representative of three independent experiments.
doi:10.1371/journal.pone.0036021.t004
Figure 4. Pretreatment with heavy metal stress increases the
sensitivity of Candida albicans to compound 33. C. albicans
cultures were incubated overnight at 30uC in the presence of cadmium
concentrations shown. After exposure to this heavy metal, C. albicans
was exposed to compound 33 at concentrations shown and incubated
at 30uC overnight. Growth was assessed using the XTT assay and
growth reduction was measured relative to the medium control. The
data are the mean 6 SD of at least three samples per treatment group
and are representative of three independent experiments. There was a
significant interaction for the two conditions (F[12, 60]=2.59, p=0.008;
ANOVA test) indicating that pre-exposure of C. albicans to heavy metal
increased sensitivity to compound 33.
doi:10.1371/journal.pone.0036021.g004
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Novel antifungal drugs are badly needed to combat the
increasing clinical challenge posed by fungal pathogens. We
utilized a S. cerevisiae reporter to create a high throughput bioassay
to identify novel antifungal compounds small molecule libraries.
Disk diffusion assays of initial hits revealed compounds 13 and 33
as two antifungal drug leads with potent and potentially broad
spectrum activity against two major fungal pathogens A. fumigatus
and C. albicans. In further testing using broth microdilution assays,
compounds 13 and 33 yielded MICs against these two fungi, other
molds and C. neoformans with similar potency to currently used
antifungals such as fluconazole and amphotericin B. Importantly,
both compounds showed fungicidal activity against mold and
yeast.
While compounds 13 and 33 exert potent, broad-spectrum
activity, they do not appear to act directly against the group III
HHKs – the mode of action that was sought in this screen. Why
did our screen not identify compounds that directly act on group
III HHKs? There may be several explanations. First, we screened
only a limited number of small molecules (,20,000). Though
sufficient for a preliminary screen, large-scale screening efforts
often include hundreds of thousands of compounds. Second, S.
cerevisiae has only one HHK, Sln1, while A. nidulans encodes 11
HHKs [31]. As a result, HHKs redundant in function to NikA
could complement its deletion explaining retained compound
activity against the DNikA strain. Third, it is possible that Hik1
overexpression ‘‘reprograms’’ S. cerevisiae to become sensitive to
compounds 13 and 33. The activity of compounds 13 and 33
therefore requires Hik1 in S. cerevisiae, but the compounds do not
directly target Hik1.
Microarray analysis revealed that compound 13 induced the up-
regulation of genes associated with an oxidative stress response.
The GSEA network analysis also showed a concordant increase in
gene families associated with an oxidative stress response.
Oxidative stress is known to damage DNA, and we found that
DNA repair-deficient fungi were much more sensitive to
compound 13 than were wild type strains. Together, these data
argue that compound 13 acts in a manner dependent on the
induction of an oxidative stress response.
C. albicans exposed to compound 33 induced transcripts
associated with the stress response to heavy metals. We also found
that pre-exposing C. albicans to heavy metal stress, by initial growth
in cadmium, increased its sensitivity to compound 33. Although
this result supports possible involvement of heavy metal stress in
the mode of action of compound 33, the finding was unanticipated
since prior work showed that pre-exposure to a given stress
engenders resistance [29]. How do we explain this discrepancy?
Vylokova et al. [29] examined osmotic stress while we studied
heavy metal stress [29]. The different stressors could explain the
discrepancy. It is also possible that residual cadmium associated
with C. albicans after pretreatment resulted in the exposure of yeast
simultaneously to heavy metal and compound 33. Similarly,
Vylokova et al. [29] observed that concurrent incubation of C.
albicans with osmotic stress together with the osmotic stress-
inducing peptide histatin 5 significantly enhanced its sensitivity.
The enhanced sensitivity of DNA repair-deficient fungi to
compound 13 is notable from a drug development standpoint,
since it suggests the compound may damage DNA. Nevertheless,
there are FDA approved antibiotics that damage DNA as part
their mode of action. Nitrofurantoin, a commonly used antimi-
crobial, damages DNA as part of its action [32]. Compound 13
contains a nitro group structurally, like in nitrofurantoin, where it
is reduced to generate oxidative stress [33]. Although compound
33 also contains nitro groups, it did not induce oxidative stress
response genes, nor did compound 33 have increased activity
against DNA repair-deficient fungi. Thus, the nitro group of
compound 13, but not 33, is likely reduced leading to oxidative
stress and DNA damage, a possible toxicity concern.
Toxicity is a concern with any potential therapeutic. Highly
toxic compounds should have been eliminated during the small
molecule secondary screen, when compounds that inhibited the
growth of wild type S. cerevisiae were removed. We also used a
standard cell membrane lysis assay to assess compound toxicity.
Amphotericin B lysed RBCs at low concentrations, whereas
compounds 13 or 33 had little effect even at the high
concentrations of 300 mg/ml. There are many different types
of cell and animal toxicity assays and we limited our initial analysis
in vitro to this standard assay, but other cell-based testing may
Figure 5. Toxicity of compounds 13 and 33. The hemolytic activity of compounds 13, 33, and amphotericin B was measured (OD405 nm) by the
release of hemoglobin from red blood cells after a one-hour exposure to compound at 37uC. 0.1% Triton X-100 was used as a control. The data are
represented as the mean 6 SD of three samples per treatment group from three independent experiments.
doi:10.1371/journal.pone.0036021.g005
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bound serum protein substantially, making systemic administra-
tion challenging, mice tolerated substantial doses with no overt
toxicity (data not shown). Thus, from the in vitro studies in
wild-type S. cerevisiae, and the studies with human RBCs, and in
mice, we conclude that compounds 13 and 33 are not general
cytotoxins.
Fungal biofilms represent one of the most challenging types
of fungal infections facing patients and physicians. Compounds
13 and 33 had robust activity against C. albicans biofilm.
Compounds 13 and 33 also were highly active in vivo in a rat
denture model of C. albicans biofilm infection. Whereas fluconazole
alone had little activity against in vitro biofilm, compounds 13 and
33 synergized significantly with fluconazole. Fluconazole-induced
oxidative stress may have enhanced its synergy with compounds
13 and 33.
The azole antifungals inhibit lanosterol 14 a–demethylase, a
crucial enzyme in the biosynthesis of ergosterol [34], but recent
studies have suggested that the generation of oxidative stress may
also be involved in their mechanism of action. For example, the
Figure 6. Activity of compounds 13 and 33 against C. albicans biofilms in vitro. (A) Six-hour in vitro C. albicans biofilms were incubated
overnight at 30uC in the presence of compound 13 or 33 (1.56–50 mg/ml) or fluconazole (62.5–500 mg/ml) as a control. After drug exposure, C.
albicans biofilm viability was assessed using XTT and growth reduction was determined relative to medium control biofilm. An unpaired t-test
revealed that C. albicans biofilm was significantly more sensitive to compounds 13 ({) and 33 ({) than to fluconazole (1000 mg/ml) (p=,0.05). The
data are the mean 6 SD of three samples per treatment group, and are representative of two independent experiments. (B) Synergistic activity of
compounds with fluconazole in C. albicans biofilm in vitro. Six-hour in vitro C. albicans biofilms were incubated overnight at 30uC with compound 13
(1.6 mg/ml) or 33 (6.3 mg/ml) and fluconazole (1000 mg/ml) alone and in combination. After drug exposure, the XTT assay was used to assess growth
reduction of the drug-treated wells relative to media control. The data are representative of a trend of synergy observed over a range of
concentrations of compounds 13 and 33 (0.4–25 mg/ml) with fluconazole (62.5–1000 mg/ml), and are displayed as the mean 6 SD of two
independent experiments.
doi:10.1371/journal.pone.0036021.g006
Table 5. Compounds 13 and 33 exert synergy with
fluconazole against in vitro Candida albicans biofilm*.
Compound EC25 EC25 with FluconazoleFIC
13 6.3060.00 1.2060.57 0.2660.09
33 4.7162.25 1.2060.57 0.3260.00
*FIC index=[EC25(A in combination)]/[EC25(A alone)]+[EC25(B in
combination)]/[EC25(B alone)], where A is compound 13 or 33 and B is
fluconazole. An index of ,0.5 indicates synergism. The results are averages 6
SD of two independent experiments.
doi:10.1371/journal.pone.0036021.t005
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the azole antifungal miconazole [35]. Furthermore, incubation
with sub-inhibitory concentrations of fluconazole caused C. albicans
to upregulate oxidative stress response genes and made the
organism more resistant to killing by phagocytes [36]. Exposure to
sub-inhibitory concentrations of fluconazole had a similar affect on
C. neoformans [37]. Oxidative stress has also been postulated to be
involved in the synergy of compounds with the azoles. For
example, the synergistic activity against C. albicans of fluconazole
with polyphenol curcumin I, a plant-derived antifungal, was
abolished by the addition of an antioxidant [38]. Thus, the
mechanism of synergy between fluconazole and compounds 13
and 33 likely involved oxidative stress.
In summary, by employing a simple high-throughput S. cerevisiae
bioassay, we discovered two compounds - 13 and 33 - with potent
fungicidal activity against yeast and molds across multiple genera
that frequently infect human patients. The compounds also work
against fungal biofilms and act in synergy with conventional
antifungal drugs. Compounds 13 and 33 therefore represent
potentially valuable antifungal drug leads.
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